Health Trials

ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer

1

Review clinical trials related to ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Available

Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer

The primary objective of this expanded access program (EAP) is to provide early access to giredestrant for participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (eBC) or locally advanced/metastatic breast cancer (LA/mBC) prior to commercial availability in the United States.

Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: Genentech, Inc.Updated: Jun 12, 2026
Eligibility criteria

Documented ER-positive tumor according to American Society of Clinical Oncology/... [+17]

Previous enrollment in Roche- or Genentech-sponsored study of giredestrant [+22]

Read more